Objective HCV prevails in uremic haemodialysis patients. The current study aimed to achieve HCV microelimination in haemodialysis centres through a comprehensive outreach programme. Design The ERASE-C Campaign is an outreach programme for the screening, diagnosis and group treatment of HCV encompassing 2323 uremic patients and 353 medical staff members from 18 haemodialysis centres. HCV-viremic subjects were linked to care for directly acting antiviral therapy or received on-site sofosbuvir/velpatasvir therapy. The objectives were HCV microelimination (>80% reduction of the HCV-viremic rate 24 weeks after the end of the campaign in centres with ≥90% of the HCV-viremic patients treated) and ‘No-C HD’ (no HCV-viremic subjects at the end of follow-up). Results At the preinterventional screening, 178 (7.7%) uremic patients and 2 (0.6%) staff members were HCV-viremic. Among them, 146 (83.9%) uremic patients received anti-HCV therapy (41 link-to-care; 105 on-site sofosbuvir/velpatasvir). The rates of sustained virological response (SVR12, undetectable HCV RNA 12 weeks after the end of treatment) in the full analysis set and per-protocol population were 89.5% (94/105) and 100% (86/86), respectively, in the on-site treatment group, which were comparable with the rates of 92.7% (38/41) and 100% (38/38), respectively, in the link-to-care group. Eventually, the HCV-viremic rate decreased to 0.9% (18/1,953), yielding an 88.3% reduction from baseline. HCV microelimination and ‘No-C HD’ were achieved in 92.3% (12/13) and 38.9% (7/18) of the haemodialysis centres, respectively. Conclusion Outreach strategies with mass screenings and on-site group treatment greatly facilitated HCV microelimination in the haemodialysis population. ClinicalTrials.gov identifier [NCT03803410][1] and [NCT03891550][2] All data relevant to the study are included in the article or uploaded as online supplementary information. The current analysis was retrieved from de-identified participant data. There is no additional information. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03803410&atom=%2Fgutjnl%2F70%2F12%2F2349.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03891550&atom=%2Fgutjnl%2F70%2F12%2F2349.atom

中文翻译：

---

建立外展、分组医疗保健系统，以实现血液透析中心尿毒症患者的 HCV 微量消除 (ERASE-C)

目的 HCV在尿毒症血液透析患者中​​普遍存在。目前的研究旨在通过全面的外展计划在血液透析中心实现 HCV 微量消除。设计 ERASE-C 运动是一项针对 HCV 筛查、诊断和集体治疗的外展计划，包括来自 18 个血液透析中心的 2323 名尿毒症患者和 353 名医务人员。HCV 病毒血症受试者与直接抗病毒治疗或接受现场索非布韦/维帕他韦治疗有关。目标是 HCV 微量消除（在活动结束后 24 周，在接受 ≥90% HCV 病毒血症患者治疗的中心，HCV 病毒血症率降低 > 80%）和“无 C 型 HD”（无 HCV 病毒血症随访结束时的受试者）。结果在介入前筛查中，178 例（7.7%）尿毒症患者和 2 例（0. 6%) 工作人员患有 HCV 病毒血症。其中，146 名（83.9%）尿毒症患者接受了抗 HCV 治疗（41 名链接到护理；105 名现场索非布韦/维帕他韦）。在完整分析组和符合方案人群中，持续病毒学应答率（SVR12，治疗结束后 12 周无法检测到 HCV RNA）分别为 89.5% (94/105) 和 100% (86/86)，在现场治疗组的发生率分别与链接护理组的 92.7% (38/41) 和 100% (38/38) 相当。最终，HCV 病毒血症率降至 0.9% (18/1,953)，较基线下降 88.3%。分别有 92.3% (12/13) 和 38.9% (7/18) 的血液透析中心实现了 HCV 微量消除和“无 C HD”。结论 大规模筛查和现场小组治疗的外展策略极大地促进了血液透析人群中 HCV 的微量消除。ClinicalTrials.gov 标识符 [NCT03803410][1] 和 [NCT03891550][2] 所有与研究相关的数据都包含在文章中或作为在线补充信息上传。当前分析是从去识别的参与者数据中检索的。没有其他信息。[1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03803410&atom=%2Fgutjnl%2F70%2F12%2F2349.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03891550&atom=%2Fgutjnl%2F70%2F1 %2F2349.atom gov 标识符 [NCT03803410][1] 和 [NCT03891550][2] 所有与研究相关的数据都包含在文章中或作为在线补充信息上传。当前分析是从去识别的参与者数据中检索的。没有其他信息。[1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03803410&atom=%2Fgutjnl%2F70%2F12%2F2349.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03891550&atom=%2Fgutjnl%2F70%2F1 %2F2349.atom gov 标识符 [NCT03803410][1] 和 [NCT03891550][2] 所有与研究相关的数据都包含在文章中或作为在线补充信息上传。当前分析是从去识别的参与者数据中检索的。没有其他信息。[1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03803410&atom=%2Fgutjnl%2F70%2F12%2F2349.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03891550&atom=%2Fgutjnl%2F70%2F1 %2F2349.atom